Alexandre Carpentier, MD, neurosurgeon at the Pitié-Salpêtrière Hospital in Paris, used an ultrasound device to open the blood-brain barrier in patients with glioblastoma — the most common and deadly type of brain tumor found in adults. He found that opening this barrier allowed significant amounts of chemotherapy to reach the tumors, when previously only miniscule amounts could reach the brain.
Focused Ultrasound Foundation in Charlottesville, Va., developed SonoCloud, the device behind this barrier-breaking technology.
To open the brain-blood barrier, researchers inject microbubbles into the bloodstream. SonoCloud, implanted near the patient’s tumor, sends ultrasonic sound waves into the brain, which excites the bubbles. The bubbles push up against the cells and cause pressure, opening the barrier for an injected drug to cross into the brain.
In his study, featured in the journal Science Translational Medicine on Wednesday, Dr. Carpentier implanted the device in 15 patients. Used during monthly chemotherapy sessions, SonoCloud showed no ill effects after six months.
Dr. Carpentier is currently designing the next phase of the clinical trial to determine how much more effective chemotherapy is when injected with an opened blood-brain barrier.
More articles on supply chain:
Some weight loss drugs more effective than others: 6 findings
FDA approves tool to detect hypoxia in brain
Researchers say new diabetes drug prevents heart attack, stroke
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.